Want to see AU:EPN full AI Analyst Report?
Top Page
Epsilon Healthcare Limited
(Sydney:EPN)
Select Model
Select Model
Rating:52Neutral
Price Target:
AU$0.03
▲(40.00% Upside)
Action:Reiterated
Date:09/24/26
The score is held back primarily by weak underlying profitability and elevated leverage despite improving revenue/margins and a meaningful cash-flow turnaround. Technicals are supportive with an established uptrend, but the high P/E and lack of dividend support create valuation risk.
Positive Factors
Revenue and Margin Recovery
TTM revenue growth and gross-margin expansion indicate stronger scale and economics than the prior period. If retained, this improvement can support operating leverage and provide a firmer base for converting renewed demand into more durable earnings.
Negative Factors
Operating Losses Persist
Revenue and gross-margin gains have not yet translated into positive operating earnings, leaving the core business economically fragile. Persistent EBIT losses reduce internal funding capacity and make the recovery dependent on further execution and continued improvement in scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Margin Recovery
TTM revenue growth and gross-margin expansion indicate stronger scale and economics than the prior period. If retained, this improvement can support operating leverage and provide a firmer base for converting renewed demand into more durable earnings.
Read all positive factors
Epsilon Healthcare Limited (EPN) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$10.12M
Dividend YieldN/A
Average Volume (3M)219.56K
Price to Earnings (P/E)86.7
Beta (1Y)-0.48
Revenue Growth121.40%
EPS GrowthN/A
CountryAU
Employees14
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)<0.01
Shares Outstanding389,104,000
10 Day Avg. Volume56,195
30 Day Avg. Volume219,562
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)6.55
Price to Sales (P/S)1.33
P/FCF Ratio-3.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Epsilon Healthcare Limited Business Overview & Revenue Model
Company Description
Epsilon Healthcare Limited operates as an Australian-based healthcare and pharmaceutical firm, with significant operations also extending into Canada. Established in 2016 and headquartered in Sydney, the company specializes in several areas: manuf...
How the Company Makes Money
null...
Epsilon Healthcare Limited Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
38
Negative
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Jun 2025 | Dec 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.37M | 9.39M | 5.60M | 6.65M | 7.11M | 5.50M |
| Gross Profit | 6.92M | 2.09M | 4.17M | 4.81M | 725.85K | 2.06M |
| EBITDA | -694.10K | -1.86M | -2.13M | -937.07K | -10.86M | -8.03M |
| Net Income | 96.58K | -1.28M | -3.25M | -1.09M | -13.29M | -9.24M |
Balance Sheet | ||||||
| Total Assets | 19.47M | 17.87M | 22.26M | 14.41M | 20.50M | 30.55M |
| Cash, Cash Equivalents and Short-Term Investments | 1.29M | 242.86K | 1.57M | 343.01K | 809.60K | 2.34M |
| Total Debt | 8.69M | 10.35M | 7.88M | 3.45M | 3.20M | 4.44M |
| Total Liabilities | 15.59M | 15.95M | 11.57M | 6.87M | 11.23M | 10.98M |
| Stockholders Equity | 3.88M | 1.91M | 10.70M | 7.54M | 9.27M | 19.57M |
Cash Flow | ||||||
| Free Cash Flow | 975.73K | -3.30M | -3.50M | -803.47K | -3.10M | -6.18M |
| Operating Cash Flow | 1.12M | -3.13M | -3.41M | -703.37K | -2.57M | -5.43M |
| Investing Cash Flow | -703.93K | 6.29M | -97.73K | -99.12K | -529.40K | -737.59K |
| Financing Cash Flow | 131.29K | -4.48M | 4.73M | 335.91K | 1.61M | 1.47M |
Epsilon Healthcare Limited Technical Analysis
Positive
0.02
Price Trends
0.02
Positive
0.02
Positive
0.02
Positive
Market Momentum
<0.01
Positive
49.08
Neutral
16.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EPN, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 49.08 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:EPN.
Epsilon Healthcare Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$149.26M | 13.80 | 19.91% | 5.25% | 12.19% | 22.36% | |
64 Neutral | AU$47.88M | 75.89 | 1.13% | 0.49% | 8.99% | 450.00% | |
52 Neutral | AU$10.12M | 86.67 | 3.34% | ― | 121.40% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$16.90M | -6.41 | -13.81% | 6.27% | 5.93% | 66.32% | |
46 Neutral | AU$57.96M | -15.22 | -1.67% | ― | 15.21% | -141.82% | |
39 Underperform | AU$21.43M | -5.07 | 4388.00% | ― | -19.73% | 50.34% |
* Healthcare Sector Average
AU:EPN
Epsilon Healthcare Limited
0.03
<0.01
8.33%
AU:VLS
Vita Life Sciences Limited
2.76
0.46
20.16%
AU:LGP
Little Green Pharma Ltd.
0.07
-0.06
-46.15%
AU:MVP
Medical Developments International Limited
0.43
-0.24
-35.61%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-15.79%
AU:IDT
IDT Australia Limited
0.04
-0.02
-30.51%
Epsilon Healthcare Limited Corporate Events
Epsilon Healthcare Director Boosts Equity Stake Through On-Market Share Purchase
Sep 17, 2026
Epsilon Healthcare Limited has disclosed a change in the shareholding of director Zoe Hutchings, in line with ASX listing rule requirements. The filing details her direct interests in fully paid ordinary shares and confirms that there were no chan...
Epsilon Healthcare Director Alan Beasley Boosts Shareholding via On-Market Purchases
Sep 10, 2026
Epsilon Healthcare Limited has disclosed a change in the holdings of director Alan Preston Beasley, who increased his direct stake in the company through on-market purchases. Over several transactions on 3, 4 and 10 September 2026, Beasley acquire...
Epsilon Healthcare Posts Record Quarter as Integrated Platform Scales
Jul 30, 2026
Epsilon Healthcare reported record customer receipts of $3.66 million for the June 2026 quarter, a 72% year‑on‑year increase and the highest quarterly figure in its history. Consolidated group revenue rose to $4.7 million for the quart...
Epsilon Healthcare Director Boosts Stake via Small Holding Facility
Jul 6, 2026
Epsilon Healthcare has disclosed a change in director Zoe Hutchings’ shareholding, reporting the off-market acquisition of 1,500,000 fully paid ordinary shares. The purchase, executed on 3 July 2026 for approximately $30,000 including broker...
Epsilon Healthcare Restructures Related-Party Funding and Secures New Debt Facility
Jun 30, 2026
Epsilon Healthcare Limited, an ASX-listed Australian healthcare group, runs a vertically integrated portfolio that includes clinic operations, pharmaceutical contract development and manufacturing, pharmacy and biotechnology therapeutic products. ...
Epsilon Healthcare completes sale of small shareholdings to streamline register
Jun 26, 2026
Epsilon Healthcare Limited has completed its small holding share sale facility, aimed at consolidating its share register and managing administrative costs associated with small shareholdings. The facility resulted in the sale of 24,487,661 fully ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.